Hepatitis C microelimination among people living with HIV in Taiwan

Figures & data

Figure 1. Study flow. Abbreviations: PLWH, people living with HIV; HCV, hepatitis C.

Table 1. Baseline characteristics of the people living with HIV who were included in this study.

Baseline characteristics	Overall cohort	HCV seronegative	HCV seropositive	HCV seroconverted
	(n = 4199)	(n = 3375)	(n = 447)	(n = 377)
Age, mean (SD), years	35.4 (10.5)	35.4 (10.6)	40.0 (10.4)	30.1 (6.8)
Male sex, n (%)	4013 (95.6)	3244 (96.1)	392 (87.7)	377 (100)
Risk group for HIV infection
Men who have sex with men, n (%)	3403 (81.0)	2829 (83.8)	213 (47.7)	361 (95.8)
Injecting drug users, n (%)	160 (3.8)	21 (0.6)	134 (30.0)	5 (1.3)
Anti-HCV positivity at enrolment, n (%)	447 (10.6)	0 (0)	447 (100)	0 (0)
HBsAg positivity at enrolment, n (%)	536/4100 (13.1)	420/3298 (12.7)	66/433 (15.2)	50/369 (13.5)

Abbreviations: HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; IQR, interquartile range; SD, standard deviation.

Figure 2. The numbers of people living with HIV (PLWH) followed, numbers of HCV RNA tests performed and annual dropout rates observed in each calendar year of follow-up. Dropouts were defined as PLWH who were included in the previous calendar year but did not have available data or samples for HCV antibody or RNA testing.

Figure 3. The evolution of the incidence and prevalence of HCV viremia during 2011–2021 among people living with HIV. PYFU, person-years of follow-up.

Figure 4. Cases of incident HCV viremia and the proportions of HCV reinfection during 2011–2021.

Data availability statement

The preliminary data of the present study have been presented as an ePoster (no. 1717) in Conference on Retroviruses and Opportunistic Infections (CROI) 2022.